DC
XBI icon

Davenport & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Davenport & Co’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03M Buy
19,133
+5,949
+45% +$804K 0.01% 480
2026
Q1 		$1.68M Buy
13,184
+2,648
+25% +$331K 0.01% 567
2025
Q4 		$1.28M Buy
+10,536
New +$1.21M 0.01% 637
2023
Q3 		– Sell
-174,589
Closed -$14.5M – 1094
2023
Q2 		$14.5M Buy
174,589
+49
+0% +$4.1K 0.11% 150
2023
Q1 		$13.3M Buy
+174,540
New +$14.5M 0.1% 156
2022
Q4 		– Sell
-8,797
Closed -$698K – 1051
2022
Q3 		$698K Sell
8,797
-92
-1% -$7.76K 0.01% 587
2022
Q2 		$660K Buy
8,889
+548
+7% +$41.1K 0.01% 603
2022
Q1 		$750K Hold
8,341
– – 0.01% 620
2021
Q4 		$934K Buy
+8,341
New +$1.01M 0.01% 586
2018
Q4 		– Sell
-15,444
Closed -$1.48M – 686
2018
Q3 		$1.48M Buy
15,444
+3,393
+28% +$329K 0.02% 272
2018
Q2 		$1.15M Sell
12,051
-4,787
-28% -$440K 0.01% 297
2018
Q1 		$1.48M Buy
16,838
+3,609
+27% +$329K 0.02% 268
2017
Q4 		$1.12M Sell
13,229
-455
-3% -$38.1K 0.01% 292
2017
Q3 		$1.18M Buy
13,684
+3,391
+33% +$272K 0.02% 282
2017
Q2 		$794K Buy
10,293
+6,118
+147% +$434K 0.01% 331
2017
Q1 		$247K Sell
4,175
-200
-5% -$13.4K ﹤0.01% 532
2016
Q4 		$258K Sell
4,375
-700
-14% -$43.2K ﹤0.01% 528
2016
Q3 		$336K Buy
5,075
+260
+5% +$16.1K 0.01% 461
2016
Q2 		$260K Buy
+4,815
New +$264K ﹤0.01% 494
2016
Q1 		– Sell
-3,265
Closed -$229K – 614
2015
Q4 		$229K Sell
3,265
-14,936
-82% -$1.02M ﹤0.01% 506
2015
Q3 		$1.13M Buy
18,201
+384
+2% +$30.3K 0.02% 255
2015
Q2 		$1.5M Buy
17,817
+6,156
+53% +$479K 0.02% 239
2015
Q1 		$876K Buy
+11,661
New +$815K 0.01% 317
2014
Q2 		– Sell
-12,459
Closed -$592K – 609
2014
Q1 		$592K Hold
12,459
– – 0.01% 345
2013
Q4 		$541K Sell
12,459
-75
-0.6% -$3.1K 0.01% 352
2013
Q3 		$540K Sell
12,534
-2,790
-18% -$113K 0.01% 340
2013
Q2 		$533K Buy
+15,324
New +$538K 0.01% 306

Other funds holding XBI

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
WAM
Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return
LHWM
Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return
MWA
MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return

Davenport & Co's XBI Position: Q2 2026 in Review

Davenport & Co increased its State Street SPDR S&P Biotech ETF (XBI) stake by 45% in Q2 2026, buying an estimated $804K and bringing the position to 19,133 shares worth $3.03M. The position accounts for 0.01% of the portfolio, ranked #480.

Davenport & Co first reported a position in XBI in Q2 2013 and has held it in 27 quarters since. The position peaked at $14.5M in Q2 2023. 201 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Davenport & Co held 19,133 shares of State Street SPDR S&P Biotech ETF worth $3.03M as of Q2 2026.
  • Davenport & Co bought 5,949 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $804K.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Davenport & Co's portfolio in Q2 2026, its #480 holding.
  • Davenport & Co first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 27 quarters since.
  • Davenport & Co's State Street SPDR S&P Biotech ETF position peaked at $14.5M in Q2 2023.
  • 201 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.